Proactive - Interviews for investors podcast

hVIVO CEO: Order book hits record £72m as H2 revenue set to nearly double

0:00
7:06
Spol 15 sekunder tilbage
Spol 15 sekunder frem
hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan spoke with Proactive's Stephen Gunnion about the company's results for the first half of 2026, its record order book, full-year guidance and the expansion of its clinical research services. Khan said hVIVO generated around £16.3 million in revenue in H1, alongside an EBITDA loss of £4.5 million, ending the period with £13 million in cash, a performance in line with the company's previous guidance that 2026 would be weighted towards the second half. A key focus was the order book. Three sizeable human challenge trial contracts, including hVIVO's first pivotal Phase 3 trial with ILiAD, took it to £65 million at the end of June, rising to £72 million including CRS Berlin, acquired in Q3. "This is the highest record order book in the company's history," Khan said, noting it was calculated using a stricter, more conservative methodology and provides visibility into the rest of 2026 as well as 2027 and 2028. For the full year, hVIVO expects second-half revenue to almost double versus H1, targeting £47 million and a low single-digit EBITDA loss, with the company expecting to turn EBITDA positive during H2. Khan also discussed hVIVO's evolution beyond its core human challenge trial business into a more integrated CRO offering spanning consulting, laboratory services and non-human challenge Phase 1 and 2 trials, with the acquisitions of CRS Mannheim, Kiel and Berlin adding capacity and therapeutic expertise, including dermatology and women's health. Watch the full interview to hear more about hVIVO’s outlook and strategy. Visit Proactive’s YouTube channel for more videos, and don’t forget to like the video, subscribe to the channel and enable notifications for future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #hVIVO #HVO #ClinicalTrials #ClinicalResearch #CRO #HumanChallengeTrials #Biotech #Biotechnology #Pharma #DrugDevelopment #Phase1 #Phase2 #Phase3 #LifeSciences #Investing #AIMStocks #ProactiveInvestors

Flere episoder fra "Proactive - Interviews for investors"